Welcome to our dedicated page for Verrica Pharmaceuticals news (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals stock.
Verrica Pharmaceuticals Inc. reports news on its dermatology therapeutics business, including commercialization of YCANTH (VP-102) for molluscum contagiosum and development of cantharidin-based therapy for common warts. Company updates also cover financial results, corporate presentations, commercial leadership and international commercialization activity.
Verrica’s pipeline news centers on VP-315 (ruxotemitide), an oncolytic peptide licensed for dermatologic oncology indications. Recurring disclosures include clinical data presentations in basal cell carcinoma, development plans for non-melanoma skin cancers and collaboration activity tied to YCANTH and its dermatology portfolio.
Verrica Pharmaceuticals (Nasdaq: VRCA) reported completion of enrollment in COVE-2, the first pivotal Phase 3 trial of YCANTH (VP-102) for treating common warts, following an interim per-protocol power analysis that recommended no additional subjects. COVE-3, the second pivotal Phase 3 trial, has surpassed 50% of its current target enrollment.
According to Verrica, topline data from COVE-2 are expected in Q1 2027, with remaining Phase 3 readouts, including COVE-3, anticipated by mid-2027. The global program includes COVE-2 and COVE-3, a long-term follow‑up study (COVE-4), and a pharmacokinetics study (COVE-5). Torii Pharmaceutical, Verrica’s Japanese development partner, will fund the first $40 million of Phase 3 costs, representing about 90% of the current trial budget, within a 50/50 cost-sharing structure. Verrica highlights common warts as a major unmet need, affecting an estimated 22 million U.S. patients and lacking any FDA-approved prescription drug therapies.
Verrica Pharmaceuticals (Nasdaq: VRCA) reported Q2 2026 total revenue of $5.9 million versus $12.7 million a year earlier, including U.S. YCANTH® net product revenue of $5.1 million, up 18.7% sequentially and 12.3% year-over-year. Dispensed YCANTH applicator units reached 19,626, rising 28.3% quarter-over-quarter and 46.1% year-over-year.
License and collaboration revenue declined to $0.8 million from $8.2 million due to the absence of a prior $8.0 million milestone. Net loss was $13.2 million versus net income of $0.2 million. Verrica entered a new credit facility of up to $27.5 million, which it believes could extend its cash runway into 2028, and it continues a global Phase 3 common warts program with topline data expected in mid-2027, while advancing Phase 3 readiness for VP-315 in basal cell carcinoma.
Verrica Pharmaceuticals (Nasdaq: VRCA) closed a new credit facility of up to $27.5 million in non-dilutive growth capital with an entity controlled by Chairman and largest shareholder Paul B. Manning. The facility is intended to support YCANTH commercialization, the global Phase 3 common warts program and general corporate purposes.
Verrica may access $12.5 million immediately, with an additional $15.0 million available upon achieving specified revenue, growth and operational milestones. Borrowings accrue interest at one-month SOFR + 8.00% (with a 4.50% SOFR floor), are payable in kind, and mature on December 31, 2030, with potential for no scheduled principal or interest payments until maturity, subject to conditions. The facility is secured by substantially all assets of Verrica and certain subsidiaries. According to Verrica, full availability could extend its cash runway into 2028 and fund Phase 3 data readouts for YCANTH in common warts expected by mid-2027.
Verrica Pharmaceuticals (Nasdaq: VRCA) will host a conference call and live webcast at 4:30 p.m. ET on Thursday, August 6, 2026, to discuss second quarter 2026 financial results and provide a corporate update. Participants can join via domestic dial-in 1-800-225-9448, international 1-203-518-9708, using conference ID: VERRICA, or through the investor relations section of the company website.
A replay of the webcast will be archived on Verrica’s website for 90 days. Verrica develops and commercializes treatments for dermatological diseases, including FDA-approved YCANTH (VP-102) for molluscum contagiosum, and is developing YCANTH for common warts and VP-315 under license from Lytix Biopharma for non-melanoma skin cancers.
Verrica Pharmaceuticals (Nasdaq: VRCA) has entered into an exclusive distribution, marketing and supply agreement with Medomie Pharma, granting Medomie rights to seek regulatory approval for and distribute YCANTH for molluscum contagiosum in Israel. Verrica will manufacture YCANTH, supply commercial product to Medomie, and receive 60% of the net selling price of YCANTH sold in Israel, plus eligibility for up to $8.2 million in regulatory and commercial milestone payments.
YCANTH, a proprietary cantharidin-based, single-use applicator treatment, is the first and only FDA-approved, healthcare professional-administered therapy for molluscum in patients aged two years and older, supported by Phase 3 trials in about 500 patients and broad U.S. insurance coverage.
Verrica Pharmaceuticals (Nasdaq: VRCA) reported dosing the first U.S. patient in COVE-3, the second pivotal Phase 3 trial of YCANTH (VP-102) for common warts. Torii Pharmaceutical recently dosed the first Japanese patient. A prior Phase 2 trial showed 51% complete clearance at Day 84. Torii will fund the first $40 million of Phase 3 costs, about 90% of the current budget, under a 50/50 cost-sharing agreement.
Verrica Pharmaceuticals (NASDAQ: VRCA) announced that President and CEO Jayson Rieger will present at the Jefferies Global Healthcare Conference in New York.
The presentation is scheduled for Thursday, June 4, 2026, at 11:05 a.m. ET, with a live and replay webcast available via Verrica’s investor website.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that President and CEO Jayson Rieger, PhD, MBA, will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026, at 1:30 p.m. ET.
A live webcast and 90-day replay will be available via Verrica’s investor relations website.
Verrica Pharmaceuticals (Nasdaq: VRCA) reported Q1 2026 revenue of $5.0 million, including U.S. YCANTH net product revenue of $4.3 million, up 16.2% sequentially and 25.4% year-over-year. Dispensed YCANTH applicator units reached 15,302, up 12.1% sequentially and 51.3% year-over-year.
YCANTH surpassed 100,000 total dispensed units since launch and was commercially launched in Japan by partner Torii. Verrica reported a GAAP net loss of $9.7 million and continues Phase 3 programs in common warts and development of VP-315 for basal cell carcinoma.
Verrica Pharmaceuticals (Nasdaq: VRCA) will present Phase 2 data on VP-315 (ruxotemitide) showing reductions in untreated basal cell carcinoma (BCC) lesions consistent with a potential abscopal effect. In 9 subjects, 14 non-treated lesions showed a 67% overall size reduction and 21% complete histologic clearance (3/14).
The poster will be presented May 15, 2026 at the SID Annual Meeting and reports an average 86% overall tumor-size reduction referenced for treated patients.